Product
Supplier
Encyclopedia
Inquiry
GDC-0152 buy - large image1
GDC-0152 buy - image1

GDC-0152

Unit Price: Get Latest Price
CAS No.:

873652-48-3

Price valid (until):

2026-08-13

Company Type:
Manufactory
Location:
United States
Qualification:
Main Products:

Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase

  • Product Description

  • Seller Information

  • Description
    ProductNameGDC-0152
    Cat NoCEI-0935
    DescriptionGDC-0152 is a potent antagonist of XIAP-BIR3, ML-IAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 28 nM, 14 nM, 17 nM and 43 nM, respectively; less affinity shown to cIAP1-BIR2 and cIAP2-BIR2. Phase 1.
    CAS No873652-48-3
    Molecular Weight498.64
    Storage2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO.
    TargetsXIAP-BIR3, ML-IAP-BIR, cIAP1-BIR3, cIAP2-BIR3
    IC5028 nM (Ki); 14 nM (Ki); 17 nM (Ki); 43 nM (Ki)
    Molecular FormulaC25H34N6O3S
    Chemical NameL-Prolinamide, N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-(4-phenyl-1,2,3-thiadiazol-5-yl)-
    SolubilityDMSO 99 mg/mL; Water 3 mg/mL; Ethanol 99 mg/mL
    In vitroGDC-0152 can block protein−protein interactions that involve IAP proteins and pro-apoptotic molecules. Using transiently transfected HEK293T cells, GDC-0152 is shown to disrupt XIAP binding to partially processed caspase-9 and to disrupt the association of ML-IAP, cIAP1, and cIAP2 with Smac. In melanoma SK-MEL28 cells, the endogenous association of ML-IAP and Smac is effectively also abolished by GDC-0152. GDC-0152 lead to a decrease in cell viability in the MDA-MB-231 breast cancer cell line, while having no effect on normal human mammary epithelial cells (HMEC). GDC-0152 is found to activate caspases 3 and 7 in a dose- and time-dependent manner. GDC-0152 is shown to induce rapid degradation of cIAP1 in A2058 melanoma cells. It effectively induces degradation of cIAP1 at concentrations as low as 10 nM, consistent with its affinity for cIAP1.
    In vivoGDC-0152 has moderate predicted hepatic clearance based on metabolic stability assays conducted using human liver microsomes. Plasma−protein binding of GDC-0152 is moderate and comparable among mice (88−91%), rats (89−91%), dogs (81−90%), monkeys (76−85%), and humans (75−83%) over the range of concentrations investigated (0.1−100 μM); higher plasma−protein binding is observed in rabbits (95−96%). GDC-0152 does not preferentially distribute to red blood cells with blood−plasma partition ratios ranging from 0.6 to 1.1 in all species tested. The pharmacokinetics for GDC-0152 is achieved with a C max of 53.7 μM and AUC of 203.5 h•μM.
    categoryInhibitors(c1514)
    cas_num873652-48-3

    Basic Info
    Product Name:

    GDC-0152

    Other Name:

    GDC-0152;L-Prolinamide, N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-(4-phenyl-1,2,3-thiadiazol-5-yl)-;(S)-1-((S)-2-Cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)pyrrolidine-2-carboxamide

    CAS No.:

    873652-48-3

    Molecular Formula:

    C25H34N6O3S

    InChIKeys:

    WZRFLSDVFPIXOV-LRQRDZAKSA-N

    Molecular Weight:

    498.646

    Exact Mass:

    498.241

    Categories:

    Inhibitors

    Characteristics
    PSA:

    145

    XLogP3:

    3.4

    Hazard Identification

    Classification of the substance or mixture

    no data available

    GHS label elements, including precautionary statements

    Pictogram(s) no data available
    Signal word

    no data available

    Hazard statement(s)

    no data available

    Precautionary statement(s)
    Prevention

    no data available

    Response

    no data available

    Storage

    no data available

    Disposal

    no data available

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase

    Location:

    Shirley, New York 11967, USA

    Payment Terms:

    TT against copy of documents,D/P

    Average lead Time:

    15

    Total Annual Revenue:

    $1 million-$2.5 million

    Year of Establishment:

    2004

    Creative Enzymes is a leading Manufactory supplier of Proline dipeptidase, Glucoamylase, BenzaMide, N-1H-pyrrolo[2,3-c]pyridin-5-yl- based in America. With a commitment to quality and customer satisfaction, Creative Enzymes has become a trusted name in the industry. Our product line includes a range of high-quality Proline dipeptidase, Glucoamylase, BenzaMide, N-1H-pyrrolo[2,3-c]pyridin-5-yl-, which are available at competitive prices. Creative Enzymes has established itself as a reliable supplier of chemical products on the echemi.com.

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.